Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations.

Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC, Vierling JM, Nguyen MH.

BMJ Open Gastroenterol. 2018 May 5;5(1):e000203. doi: 10.1136/bmjgast-2018-000203. eCollection 2018.

2.

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis.

Tran SA, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S, Henry L, Nguyen MH.

BMJ Open Gastroenterol. 2018 Mar 20;5(1):e000192. doi: 10.1136/bmjgast-2017-000192. eCollection 2018.

3.

Reversals and limitations on high-intensity, life-sustaining treatments.

Chavez G, Richman IB, Kaimal R, Bentley J, Yasukawa LA, Altman RB, Periyakoil VS, Chen JH.

PLoS One. 2018 Feb 28;13(2):e0190569. doi: 10.1371/journal.pone.0190569. eCollection 2018.

4.

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.

Nguyen P, Vutien P, Hoang J, Trinh S, Le A, Yasukawa LA, Weber S, Henry L, Nguyen MH.

BMJ Open Gastroenterol. 2017 Dec 20;4(1):e000181. doi: 10.1136/bmjgast-2017-000181. eCollection 2017.

5.

Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.

Le AK, Zhao C, Hoang JK, Tran SA, Chang CY, Jin M, Nguyen NH, Yasukawa LA, Zhang JQ, Weber SC, Garcia G, Nguyen MH.

Aliment Pharmacol Ther. 2017 Sep;46(6):605-616. doi: 10.1111/apt.14241. Epub 2017 Aug 2.

PMID:
28766727

Supplemental Content

Loading ...
Support Center